Posted: 14 December
Dimertix Limited a biopharmaceutical company with late-stage clinical assets in inflammatory diseases, confirmed that the CLARITY 2.0 investigator-led study of DMX-200200 in COVID-19 patients has reported top line data. In total, 49 patients were recruited into the study, with 25 receiving DMX-200 and 24 receiving a placebo for 28 days. All patients were treated concurrently with an angiotensin receptor blocker (ARB). Protocol adherence was high and medication adherence complete.
DMX-200 appeared to be safe and well-tolerated, with no notable variation in the incidence or severity of adverse events between treatment with DMX-200 or placebo. There were no serious adverse events related to the drug reported. The safety data findings are entirely consistent with existing and growing strong safety profile of DMX-200.
